Table of Content

1. Brief Introduction To CD137
1.1 Clinical Overview
1.2 Biological History Of CD137
1.3 CD137 Hosting An Era Of Agonists Over Antagonists
1.4 Bi-Directional Signaling In CD137


2. Global CD137 Antibody Market Outlook
2.1 Current Research & Market Scenario
2.2 Future Commercialization Opportunities


3. CD137 Antibody Clinical Developments by Regions
3.1 China
3.2 US
3.3 South Korea
3.4 Europe
3.5 Australia


4. Role Of CD137 & Clinical Progress By Indication
4.1 Cancer
4.1.1 Leukemia
4.1.2 Lymphoma
4.1.3 Lung Cancer
4.1.4 Melanoma
4.1.5 Breast Cancer
4.1.6 Colorectal Cancer

4.2 Autoimmune & Inflammatory Diseases
4.3 Microbial Infections
4.3.1 Viral Infections
4.3.2 Bacterial infections



5. Global CD137 Antibodies Clinical Trials Overview
5.1 By Company
5.2 By Country
5.3 By Indication
5.4 By Phase
5.5 By Patient Segment


6. CD137 Inhibitors Clinical Trials Insight By Company, Country, Indication & Phase
6.1 Research
6.2 Preclinical
6.3 Phase I
6.4 Phase I/II
6.5 Phase II


7. CD137 Targeting Proprietary Technology Platforms By Companies


8. CD137 Therapeutic Approaches By Antibodies Classification
8.1 Monoclonal Antibody Based Strategies
8.2 Bispecific Antibody Centered Approaches
8.3 Trispecific Antibody Established Strategies
8.4 Tetraspecific Antibody Strategies


9. Combination Therapies With CD137 Antibodies


10. Competitive Landscape
10.1 ABL Bio
10.2 Adagene
10.3 Alligator Bioscience
10.4 BeiGene
10.5 Bicycle Therapeutics
10.6 BioNTech
10.7 Biotheus
10.8 Crescendo Biologics
10.9 Eutilex
10.10 F-star Therapeutics
10.11 Genmab
10.12 I-MAB Biopharma
10.13 Lyvgen Biopharma
10.14 OriCell Therapeutics
10.15 Pieris Pharmaceuticals
10.16 Shanghai Henlius Biotech
10.17 Sichuan Baili Pharmaceutical
10.18 SystImmune
 



List of Figures

Figure 1-1: Anti-CD137 Monoclonal Antibody - Immune Regulation Mechanisms
Figure 1-2: Schematic Depiction Of Bidirectional Signaling By CD137–CD137L

Figure 2-1: CD137 First Approval Sales Estimate – First 12 Months & First 24 Months (US$ Million)

Figure 4-1: GNC-035-105 Phase Ib/II (NCT05944978) – Initiation & Completion Year
Figure 4-2: GNC-035-101 Phase I (NCT05944978) – Initiation & Completion Year
Figure 4-3: GNC-038-101 Phase I (NCT04606433) – Initiation & Completion Year
Figure 4-4: ACIT001 Phase Ib/II (NCT03938987) – Initiation & Completion Year
Figure 4-5: BP41072 Phase I/II (NCT04077723) – Initiation & Completion Year
Figure 4-6: YH004 Phase I (NCT05564806) – Initiation & Completion Year
Figure 4-7: EU-CTS101-I-01 Phase I/II (NCT04903873) – Initiation & Completion Year
Figure 4-8: GCT1046-04 Phase 2 (NCT05117242) – Initiation & Completion Year
Figure 4-9: GCT1046-04 Phase 2 (NCT05117242) – Initiation & Completion Year
Figure 4-10: GCT1046-04 Phase II (NCT05117242) – Initiation & Completion Year
Figure 4-11: Phase I/II (NCT03809624) – Initiation & Completion Year
Figure 4-12: INBRX-105 Phase I (NCT03809624) – Initiation & Completion Year
Figure 4-13: C-1100-01 Phase I (NCT04121676) – Initiation & Completion Year
Figure 4-14: QLF31907-201 Phase 2 (NCT05823246) – Initiation & Completion Year
Figure 4-15: AVIATOR Phase 2 (NCT03414658) – Initiation & Completion Year
Figure 4-16: ADG106-T6002 Phase 1/2 (NCT05275777) – Initiation & Completion Year
Figure 4-17: YH32367-101 Phase I/II (NCT05523947) – Initiation & Completion Year
Figure 4-18: GNC-035-103 Phase 1 (NCT05160545) – Initiation & Completion Year
Figure 4-19: BP42675 Phase Ib (NCT04826003) – Initiation & Completion Year
Figure 4-20: EU-CTS101-I-01 Phase I/II (NCT04903873) – Initiation & Completion Year
Figure 4-21: 2017-0180 Phase 1 (NCT03290937) – Initiation & Completion Year

Figure 5-1: Global – CD137 Targeting Antibodies Clinical Pipeline by Company (Numbers), 2024
Figure 5-2: Global – CD137 Targeting Antibodies Clinical Pipeline by Country (Numbers), 2024
Figure 5-3: Global – CD137 Targeting Antibodies Clinical Pipeline by Indication (Numbers), 2024
Figure 5-4: Global – CD137 Targeting Antibodies Clinical Pipeline by Phase (Numbers), 2024
Figure 5-5: Global – CD137 Targeting Antibodies Clinical Pipeline by Patient Segment (Numbers), 2024

Figure 7-1: Adagene – Anti CD137 NEObody ACG106
Figure 7-2: Adagene – Anti CD137 POWERbody ADG206
Figure 7-3: Genmab - DUObody Production Process
Figure 7-4: Crescendo Biologics - Humabody Structure
Figure 7-5: Crescendo Biologics - CB307 Structure
Figure 7-6: Numab Therapeutics - MATCH Format
Figure 7-7: Systimmune – GNC-039 Structure
Figure 7-8: Systimmune – GNC-035 Structure
Figure 7-9: Systimmune – GNC-038 Structure
Figure 7-10: Merus – Multiclonics Structure
Figure 7-11: Chugai Pharmabody Research - Dual-Ig? Technology
Figure 7-12: Eutilex - Costim Platform Technology

Figure 8-1: ATOR-1017 – Mechanism Of Action
Figure 8-2: EU101 – Mode Of Action
Figure 8-3: LVGN6051 – Mechanism Of Action
Figure 8-4: ABL503 – Structure & Mechanism Of Action
Figure 8-5: FS120 – Improving PD-1 & Chemotherapy Responses
Figure 8-6: MP0310 – Mechanism Of Action

List of Tables

Table 4-1: Lymphoma – Clinical Trials Underway for GNC-038 & GNC-035

Table 8-1: Bispecific Antibodies Targeting CD137/4-1BB in Clinical Trials
Table 8-2: Trispecific Antibodies Targeting CD137/4-1BB in Clinical Trials
Table 8-3: Tetraspecific Antibodies Targeting CD137/4-1BB in Clinical Trials

Table 9-1: Ongoing Clinical Trials Evaluating CD137 Antibody Combinations